L3VLUP
ProSign in

PCRX · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PCRXLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PCRX
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterPCRXLLY
Q3 20205 holders, $344m33 holders, $14.1bn
Q4 20205 holders, $335m29 holders, $17.3bn
Q1 20214 holders, $313m24 holders, $23.0bn
Q2 20216 holders, $303m24 holders, $27.8bn
Q3 20216 holders, $251m31 holders, $29.9bn
Q4 20216 holders, $269m31 holders, $34.7bn
Q1 20226 holders, $332m24 holders, $35.3bn
Q2 20225 holders, $239m33 holders, $42.7bn
Q3 20225 holders, $206m31 holders, $43.4bn
Q4 20225 holders, $144m31 holders, $46.6bn
Q1 20236 holders, $174m33 holders, $44.3bn
Q2 20238 holders, $174m37 holders, $59.6bn
Q3 20235 holders, $111m44 holders, $67.6bn
Q4 20235 holders, $102m45 holders, $73.6bn
Q1 20243 holders, $108m41 holders, $95.3bn
Q2 20244 holders, $113m43 holders, $110bn
Q3 20244 holders, $41m45 holders, $107bn
Q4 20244 holders, $68m46 holders, $93.9bn
Q1 20257 holders, $178m42 holders, $98.4bn
Q2 20255 holders, $117m43 holders, $93.2bn
Q3 20254 holders, $109m39 holders, $86.7bn
Q4 20255 holders, $57m41 holders, $123bn
Q1 20263 holders, $45m39 holders, $106bn
Q2 20263 holders, $49m44 holders, $132bn
PCRX

Pacira Biosciences Inc

Holders
4
Reported value
$113m
Buyers
3
Sellers
1

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
43
Reported value
$110bn
Buyers
29
Sellers
17

Breadth +12 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only PCRX (2)

Baillie Gifford & Co, Renaissance Technologies LLC

Only LLY (41)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Millennium Management LLC, and 16 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →